Eli Lilly (LLY) closed the most recent trading day at $1,027.51, moving +1.8% from the previous trading session. This change outpaced the S&P 500's 1.07% loss on the day. At the same time, the Dow ...

In the latest trading session, Eli Lilly (LLY) closed at $1,056.88, marking a +1.45% move from the previous day. This move outpaced the S&P 500's daily gain of 0.79%. Elsewhere, the Dow saw an upswing ...

Eli Lilly (LLY) shares spiked ~3% on Thursday after the obesity drugmaker posted Phase 3 data showing its next-gen therapy retatrutide can generate up to 24% of weight loss, a “best-in-class" efficacy ...

Eli Lilly (LLY) shares clocked seven straight sessions of losses on Friday, as the stock was 0.5% lower at $1,009.15. The pharmaceutical giant lost 8% in the preceding six sessions. Overall, the stock ...

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term. On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from ...

Eli Lilly and Co. (NYSE: LLY) on Tuesday today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. The synthetic medicine active pharmaceutical ...

Eli Lilly and Co (NYSE: LLY) on Thursday shared topline results from the Phase 3 TRIUMPH-4 trial evaluating the two highest investigational doses of retatrutide. Retatrutide is a GIP, GLP-1, and ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

FDA chief's office said it wants to cut the filing review from 60 days to one week The office said it may cut those reviews to two or three weeks based on complexity The agency could decide on Lilly's ...